---
search:
  boost: 3
---

# Pulmonary Arterial Hypertension

This is a subcategory of Cardiovascular Agents.

## Decision Trees

- [Cardiovascular - Pulmonary Arterial Hypertension- Non-Preferred Products- Adempas, Bosentan, Epoprostenol, Opsumit, Tracleer Susp, Treprostonil, Tyvaso, Uptravi, Ventavis](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURU1CRzJLWk84UTVFMzBBME5JRzlOV1JUMSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Cardiovascular - Pulmonary Arterial Hypertension - Preferred Products - Ambrisentan, Sildenafil, Tadalafil, Tracleer Tab](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQkxFNzBSVllHRTVQUFlESkVFMEM1RENMQyQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Cardiovascular - Pulmonary Arterial Hypertension - Sildenafil Susp, Tadliq](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNU9MSExBTVQ5V0tTQVIzSFlDVzNLV01aVSQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                        | Generic Name | Quantity | Time (Days) |
|:---------------------------------|:-------------|:--------:|:-----------:|
| Ambrisentan <sup>PA</sup>        |              |          |             |
| Sildenafil <sup>PA</sup>         |              |          |             |
| Sildenafil Susp <sup>AR PA</sup> |              |          |             |
| Tadalafil <sup>PA</sup>          |              |          |             |
| Tadliq <sup>AR PA</sup>          |              |          |             |
| Tracleer Tab <sup>BvG PA</sup>   |              |          |             |

### Non-Preferred

| Non-Preferred                                                                            | Generic Name | Quantity | Time (Days) |
|:-----------------------------------------------------------------------------------------|:-------------|:--------:|:-----------:|
| Adempas                                                                                  |              |          |             |
| <span title = "Brand Preferred: Tracleer Tab">Bosentan</span> <sup>Brand Preferred</sup> |              |          |             |
| Epoprostenol                                                                             |              |          |             |
| Opsumit                                                                                  |              |          |             |
| Tracleer Susp                                                                            |              |          |             |
| Treprostinil                                                                             |              |          |             |
| Tyvaso                                                                                   |              |          |             |
| Uptravi                                                                                  |              |          |             |
| Ventavis                                                                                 |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

### Grandfathering*

Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug previously but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.

**All Authorizations**: Must be precribed in accordance with FDA approved labeling

## Criteria

### Clinical PA

Clinical PA Criteria

Must provide documentation of NYHA Functional Class for Pulmonary Hypertension and symptoms experienced by patient

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^30 days^^ with at least ^^two preferred^^ drugs, ^^one^^ of which must be a phosphodiesterase-5 inhibitor
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Additional Information

- Patients who have class III or IV symptoms defined by the NYHA Functional Class for Pulmonary Hypertension may be authorized for inhalation or intravenous agents

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**AR** - Sildenafil Susp and Tadliq: a PA is required for patients 6 years and older

## Links

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=24){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=13){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
